The FDA has reportedly approved an AI product that predicts cognitive decline

The US government has reportedly approved AI-based memory loss prediction software for the first time. Darmiyan, a San Francisco-based brain imaging analytics company, says the FDA has granted De Novo approval for its product BrainSee. The software platform assigns “an objective score that predicts the likelihood of progression from aMCI to Alzheimer’s dementia within 5 years,” according to the medical company. Fierce Biotech first reported the announcement.

Darmiyan says BrainSee can predict memory loss progression using clinical brain MRIs and cognitive tests, which are already standard for patients worried about early signs of decline. After the program analyzes the imaging and cognitive assessments, it assigns a predictive score indicating the patient’s odds of memory deterioration within the following five years. At least in theory, that would lead to early treatment for some and peace of mind for others.

“This shifts the patient experience from prolonged anxiety to proactive management, which is crucial in an era of emerging Alzheimer’s treatments where accurate prognosis can help determine suitable treatment candidates,” Darmiyan wrote in a press release announcing the FDA approval. “The economic impact of BrainSee will be significant for all stakeholders in healthcare, promising to reduce the billions of dollars annually spent on Alzheimer’s care, through more effective management and treatment.”

The FDA’s “De Novo” designation means the product has no clear market predecessors but has proven its effectiveness and safety in clinical trials. BrainSee first received FDA “breakthrough” designation in 2021, an earlier stage of the approval path for a first-of-its-kind treatment. 

Darmiyan says BrainSee is fully automated and provides results on the same day the scans and cognitive test scores are entered. The company views the tech as shifting the treatment of mild / early cognitive decline from biomarker-based methods to “non-invasive and actionable forecasts of future improvement or progression.”

This article originally appeared on Engadget at https://www.engadget.com/the-fda-has-reportedly-approved-an-ai-product-that-predicts-cognitive-decline-184534034.html?src=rss https://www.engadget.com/the-fda-has-reportedly-approved-an-ai-product-that-predicts-cognitive-decline-184534034.html?src=rss
Creato 1y | 12 gen 2024, 20:40:31


Accedi per aggiungere un commento

Altri post in questo gruppo

Switch 2 Pro Controller review: Nintendo's best gamepad simply costs too much

For as long as I can remember, Nintendo's gamepads have been a core part of my life. The NES's original rectangular controller was awfully unergonomic, but I still loved it, and it set me down the

13 giu 2025, 15:20:24 | Engadget
The Morning After: Our verdict on the Switch 2

You forget how much of a hit, how much of a turnaround, the Nintendo Switch turned out to be. After the major wobble (and baffling form factor) of the Wii U, Nintendo came back with a hybrid consol

13 giu 2025, 13:10:07 | Engadget
Engadget Podcast: Switch 2 review, Summer Game Fest and WWDC 2025

It's been a busy week! In this episode, Devindra and Senior Editor Jessica Conditt dive into their final thoughts on the Switch 2, as well as Jess's time covering Summer Game Fest. We also put a bo

13 giu 2025, 13:10:06 | Engadget
iOS 26 will fit CarPlay to better match the shape of your car's screen

iOS 26 has introduced a new feature that will help CarPlay take better advantage of the shape of your vehicle's display, Apple announced at

13 giu 2025, 13:10:05 | Engadget
Eufy's 3-in-1 robot vacuum drops to a record-low price

Robot vacuums can save you a ton of time by automating a regular chore you'd otherwise have to do manually. But you may sometimes want a handheld or cordless vacuum to quickly clean up small messes

13 giu 2025, 13:10:04 | Engadget